FRIEDREICH'S ATAXIA RESEARCH ALLIANCE
FARA - Friedreich's Ataxia Research Alliance
522122720
1998
SPRINGFIELD, VA 22151
curefa.org
CureFA
1183319
Podobné organizace
Curefa Foundation Inc |
|
National Ataxia Foundation Incorporated |
|
Ataxia Telangiectasia Children's Project, Inc. |
|
Place of Purpose Community |
|
National Ataxia Foundation Incorporated |
Podobné organizace global
ACTION FOR A-T |
|
THE EHLERS-DANLOS SOCIETY |
|
ATACSIA A FI / ATAXIA AND ME |
|
Fondation De L'Ataxie Charlevoix-Saguenay |
|
Paediatrio Ltd |
Podobná návštěvnost
Český rybářský svaz, z. s., Středočeský územní svaz |
|
Česká unie sportu, z.s. |
|
Pražský volejbalový svaz z. s. |
|
PARALELNÍ POLIS, z.s. |
|
Spolek LÍPA 2015 |
Podobně sociální sítě (14247)
DĚTI BEZ HRANIC - táborový spolek15000 |
|
NAUTICA KARVINÁ z.s.15000 |
|
HC Skulls Hlinsko, z.s.15000 |
|
ADRA, o.p.s.15000 |
|
Unie ROSKA - reg. org. ROSKA BRNO-MĚSTO, z.p.s.15000 |
Více Ostatní lékařský výzkum j. n. (jiné než specifikované)
ULZIBAT.CZ z.s.Praha |
|
Nadační fond Karla LewitaDobřichovice |
|
CZECHIMPLANT, z.s.Kladno |
|
Za novým úsměvem klientů a přátel rozštěpového centra Praha z.s."Česká Lípa |
|
Sdružení pro srdeční rytmus, spolekPraha |
Novinky
Three clinical research sites in Australia are recruiting participants for a phase 1, multiple ascending dose study of DT-216P2 (a GeneTAC® small molecule ). This study is sponsored by Design Therapeutics. Expansion to an additional country is anticipated later this year. The study is now recruiting participants between the ages of 18 and 65 years old with a genetically confirmed FA diagnosis. Participants must be able to perform basic daily care with minimal assistance and meet other study-specified eligibility criteria. Study participants will be enrolled for up to 12 weeks. Click here for more information and eligibility requirements: https://ow.ly/vjBh50VWCAj Anyone considering participating in a clinical trial should discuss the matter with their physician. FARA does not endorse or recommend any particular studies. (fb)
If you missed the first session of the 2025 FARA Flash Talks, the recording is now available! This two-part series covers important aspects of FARA-funded FA research, from genetics and disease mechanisms to neuro-imaging and therapeutic approaches. https://ow.ly/MF4650VWAWH And don't miss the second FARA Flash Talk session next Wednesday, May 28. To register, please click here: https://ow.ly/Oj9450VWAWI (fb)
Poslední komentáře
Absolutely inspired by the work being done by FARA! Together, we can bring hope and change to the FA community. Let’s keep pushing for a cure! 💪💙detail |
|
So grateful for this amazing community and all the advancements in Friedreich's ataxia research! Every effort counts, and we are one step closer to a cure! 🌟 #CureFAdetail |
Poslední diskuze
- How can we better engage the community in fundraising efforts to support ongoing research for Friedreich's Ataxia?Odpovědí: 3, Naposledy před 1 den detail |
|
- What role does advocacy play in accelerating the approval process for new treatments for Friedreich's Ataxia?Odpovědí: 3, Naposledy před 1 den detail |
V okolí
17
500
4.5
SPRINGFIELD
O společnosti
- H99 -
Powering research to treat Friedreichs Ataxia Dear FA family Although the circumstances of our meeting are difficult we are glad that you have found the Friedreich039s Ataxia Research Alliance. Leading to the discovery and advancement of treatments for FA Join a passionate community and change the course of this rare disease Apply for a research grant and make an impact Work with an experienced research community Utilize FARA resources to help optimize the pace of research Fuel research progress Share your story Engage with our amazing community Latest news from our community. March 2025 Advocacy Newsletter Press Release Community Update Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results SKYCLARYS omaveloxolone Approval by Health Canada Ushers in a New Era for Friedreichs Ataxia Treatment in Canada Design Therapeutics Initiated Phase 1 Single Ascending Dose Trial of DT216P2 in Healthy Volunteers FA Community Statement from Biogen Press Release Community Statement PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich039s Ataxia February 2025 Advocacy Newsletter Job Posting Development Manager Major Gifts Letter to the FA Community from Astellas Pharma Webinar Recording PTC Therapeutics Vatiquinone Program January 2025 Update Janaury 2025 Advocacy Newsletter 95 Million 1 18 1500 198. 5M 38 Our upcoming events.
Ostatní lékařský výzkum j. n. (jiné než specifikované)
